Shah Shagun B, Pahade Akhilesh, Chawla Rajiv
Department of Anaesthesiology, Rajiv Gandhi Cancer Institute and Research Centre, Rohini, New Delhi, India.
J Anaesthesiol Clin Pharmacol. 2020 Oct-Dec;36(4):471-476. doi: 10.4103/joacp.JOACP_379_20. Epub 2020 Nov 5.
HCQ gained importance following the National Task Force advisory as an anti-SARS-Cov-2 (coronavirus disease-2019 [COVID-19]) drug for frontline healthcare workers (including anesthesiologists). Report of a young anesthesiologist in Assam developing cardiac arrest following HCQ intake for COVID-19 prophylaxis made us even more concerned. A conscious decision has been made by a large majority among us--to have or not to have HCQ. However, less severe complications such as gastrointestinal upset, skin-rash, visual-disturbance, headache, and dizziness even if experienced by HCQ users were likely to go unreported unless shared. The present survey was conducted to assess the prevailing perception among Indian anesthesiologists about HCQ's preventive effect against COVID-19. The information has been pooled together and discussed in this study.
A total of 247 respondents participated in this pan-India survey. The survey questionnaire was prepared using "Google Forms" and conducted via links delivered through WhatsApp and electronic-mail.
55.9% (138/247) of the respondents had consumed HCQ, 38% (94/247) did not, and 6.1% (15/247) were undecided at the time of responding to the survey. In total, 47 respondents who ingested HCQ reported a side-effect, gastritis being the commonest (31).
The evidence for the effectiveness of HCQ against COVID-19 in India is reportedly as strong and weak as other drugs that have been promoted. The survey highlights the reasons consumption of HCQ and represents the opinion of 247 practicing Indian anesthesiologists. It informs the benefits and side effects of HCQ, which can help others in reaching a balanced decision.
在国家特别工作组发布建议后，羟氯喹（HCQ）成为一线医护人员（包括麻醉医生）抗击严重急性呼吸综合征冠状病毒2（SARS-CoV-2，即2019冠状病毒病[COVID-19]）的药物，其重要性日益凸显。一名来自阿萨姆邦的年轻麻醉医生在服用HCQ预防COVID-19后发生心脏骤停的报告，让我们更加担忧。我们大多数人都做出了一个慎重的决定——服用或不服用HCQ。然而，即使HCQ使用者出现了诸如胃肠道不适、皮疹、视觉障碍、头痛和头晕等不太严重的并发症，若不分享，这些情况可能也不会被报告。本次调查旨在评估印度麻醉医生对HCQ预防COVID-19效果的普遍看法。本研究汇总并讨论了相关信息。
共有247名受访者参与了这项全印度范围的调查。调查问卷通过“谷歌表单”制作，并通过WhatsApp和电子邮件发送的链接进行调查。
55.9%（138/247）的受访者服用过HCQ，38%（94/247）未服用过，6.1%（15/247）在回答调查问卷时未做决定。总共有47名服用HCQ的受访者报告出现了副作用，胃炎最为常见（31例）。
据报道，在印度，HCQ对COVID-19有效性的证据与其他被推广的药物一样，有强有弱。该调查突出了服用HCQ的原因，并代表了247名执业印度麻醉医生的意见。它告知了HCQ的益处和副作用，有助于其他人做出权衡。
